Damon Runyon Researchers

Meet Our Scientists
Eric S. Fischer, PhD

Cancer therapies that target a specific gene product (targeted therapies), for example the oncogenic BCR-ABL by Gleevec, are now a very successful paradigm in cancer treatment. However, many known cancer-driving proteins are recalcitrant to the development of traditional small molecule inhibitors. In recent years, novel pharmacologic strategies have been proposed and developed to tackle this pervasive problem in drug development. One such novel pharmacologic modality is called “degraders,” small molecules that hijack the cellular waste disposal system – the ubiquitin proteasome system – to remove a cancer-causing protein from the cell. While the concept has shown incredible success in the case of lenalidomide (Revlimid) for the treatment for multiple myeloma, our understanding of the underlying mechanism is insufficient to broadly apply degraders to cancer treatment. Dr. Fischer’s research will expand our molecular understanding for the mechanism of action of degraders, and further develop a novel class of small molecule degraders to target oncogenic gene products. He anticipates that this work will contribute to the development of novel medicines for many cancers.

Project title: "Novel mechanisms for small molecule induced targeted degradation of RRM family proteins"
Institution: Dana-Farber Cancer Institute
Award Program: Innovator
Cancer Type: All Cancers
Research Area: Structural Biology